Section 174 R&D Amortization — Advisory Record (TCJA/OBBBA Impact)
Internal Revenue Service
Depends on R&D spend
Researched for this program: 5 rejection traps · 5 required documentsWhat decides this award ↓
Critical advisory: R&D expensing rules changed
ADVISORY: §174 is not a credit — it governs the deductibility of research and experimental (R&E) expenditures. The TCJA (2017) eliminated immediate expensing starting January 1, 2022, requiring domestic R&D costs to be amortized over 5 years (15 years for foreign R&D). This was the most consequential TCJA change for tech, biotech, and software companies. The OBBBA (One Big Beautiful Bill Act, signed July 4, 2025) restored immediate expensing for DOMESTIC R&E expenditures incurred after December 31, 2024 and provided retroactive relief for tax years 2022–2024 for qualifying small businesses (≤$31M average annual gross receipts). Foreign R&D remains on 15-year amortization. This record exists to flag the §174 situation to founders who may be unaware of the cash-flow trap and the OBBBA relief.
- Funding type
- Program
- Level
- Federal
- Amount
- Not a credit. §174 governs deductibility of R&E expenditures. Under TCJA (2022–2024): domestic R&D amortized over 5 years (60-month straight-line from midpoint of first year). Under OBBBA restoration (effective for domestic R&E after December 31, 2024): immediate expensing in year incurred. Retroactive relief: qualifying small businesses (≤$31M avg annual gross receipts for 3 prior tax years) may file amended returns for 2022, 2023, and 2024 to deduct previously-amortized domestic R&E expenditures in full.
- Realistic amount
- A SaaS startup with $2M/yr in qualifying domestic R&D wages: under TCJA amortization, only $200K was deductible in Year…
- Deadline
- Ongoing — §174 applies to all domestic R&E expenditures. Retroactive relief for 2022–2024: qualifying small businesses should file amended returns (Form 1040-X for pass-throughs, Form 1120-X for C-corps) or use the §174 election available on the original return for still-open years.
- Status
- active
- States
- Nationwide
- Payment model
- tax offset
Who qualifies
- OBBBA immediate expensing restoration: any US taxpayer (C-corp, S-corp, partnership, sole proprietor) with domestic R&E expenditures paid or incurred after December 31, 2024
- Domestic R&E includes: wages for employees engaged in research and experimentation, supplies used in research, a portion of costs to operate research facilities, and 65% of payments to US contract researchers
- Foreign R&E expenditures (research conducted outside the US) remain on 15-year amortization — OBBBA did NOT restore immediate expensing for foreign R&D
- Retroactive 2022–2024 relief: taxpayer must have ≤$31 million average annual gross receipts for the 3-year period preceding the tax year in question (the small business threshold)
- Retroactive relief: the taxpayer may file an amended return (or make an election on an original return for still-open years) to deduct domestic R&E expenditures in full for 2022, 2023, and 2024
- Note: §174 deductibility and §41 R&D credit qualification overlap but are NOT the same — an expense can qualify under both, neither, or just one. The §174 changes affect the DEDUCTION; §41 credit computation is separate
What it covers
Eligible expenses
- Wages paid to US employees performing, directly supervising, or directly supporting qualified domestic research and experimentation
- Supplies consumed in domestic research activities
- Costs to operate domestic research facilities (utilities, facility overhead allocated to research)
- 65% of payments to US contract researchers performing qualified domestic R&E
- Software development costs meeting the §174 R&E definition (including internal-use software in some circumstances)
Ineligible expenses
- Foreign R&D expenditures — these remain on 15-year amortization under both TCJA and OBBBA (not restored)
- Funded research (amounts for which the taxpayer is entitled to reimbursement from another party regardless of success)
- Quality control testing after commercial production begins
- Market research, advertising, and customer feedback activities
- Acquisition of another's patent, model, production, or process
How to apply
-
1
Identify whether your R&D was amortized under TCJA (2022–2024)
Review your 2022, 2023, and 2024 federal returns. If you had domestic R&E expenditures after January 1, 2022, they were placed on 5-year amortization schedules under the TCJA rule. Identify the amount deferred (the un-amortized carryforward) on each return. This is the pool eligible for retroactive recovery.
~4 hrs
-
2
Determine if you qualify for retroactive small-business relief
Calculate your average annual gross receipts for the 3 tax years preceding 2022, 2023, and 2024 respectively. If each calculation yields ≤$31 million, you qualify. This includes gross receipts of all members of a controlled group (don't look just at your entity in isolation if you're part of a larger structure).
~2 hrs
-
3
File amended returns for 2022–2024 (if qualified and open years remain)
Prepare Form 1040-X (individuals/pass-throughs) or Form 1120-X (C-corps) for each open year. Reverse the prior amortization schedule and claim the full domestic R&E deduction. The refund or credit overpayment can be applied to future estimated taxes. Note: the 3-year amended-return deadline means 2022 calendar-year returns must be amended by approximately April 15, 2026. Act quickly for 2022.
~8 hrs
-
4
Adjust 2025+ tax planning for restored immediate expensing
For tax year 2025 and beyond, domestic R&E expenditures are immediately deductible in the year incurred — revert to pre-TCJA treatment. Update your tax projection model and estimated tax payments accordingly. If you had built amortization schedules into your 2025 projections, remove them.
~3 hrs
-
5
Coordinate §174 expensing with §41 R&D credit calculation
The §41 R&D credit and §174 deduction overlap in scope but are computed differently. Under the §280C election, you can reduce the §41 credit by 21% (for C-corps) and preserve the full §174 deduction. Without the §280C election, you must reduce the §174 deduction by the §41 credit amount. Have your CPA model both scenarios for optimal after-tax position.
~3 hrs
The 2022 amended-return window closes around April 2026 for calendar-year filers. If your business had >$500K in domestic R&D wages in 2022 and qualifies as a small business (≤$31M receipts), filing now could generate a six-figure refund. Don't wait.
Deadline & timing
OBBBA enacted July 4, 2025. Immediate expensing restoration applies to domestic R&E expenditures paid or incurred after December 31, 2024 (i.e., beginning tax year 2025 for calendar-year filers). Retroactive relief for 2022–2024: small businesses with ≤$31M average annual gross receipts may elect to take the full deduction retroactively by filing amended returns. The statute of limitations for amended returns (generally 3 years from original filing) governs which years remain open — consult a CPA promptly if 2022 returns are approaching their amended-return deadline. Foreign R&D expenditures remain on 15-year amortization under both TCJA and OBBBA — not restored.
Not accepting applications right now — get one email when it reopens
GrantCompass tracks Section 174 R&D Amortization — Advisory Record (TCJA/OBBBA Impact)’s application windows in the live catalog. Leave an email and we’ll tell you the day the next window opens.
Free. One email when the window moves, deadline warnings on your watchlist, and the monthly closing-soon digest. Unsubscribe anytime.
Programs that stack well
Related programs
This program is not taking applications today — these are
Alternatives computed from the live GrantCompass catalog on August 25, 2026 — all 183 open grant programs · filter the database.
Explore more funding
Last reviewed 2026. GrantCompass is an independent funding-discovery tool and is not affiliated with any government agency. Always confirm details on the official program page.